NPI: 1598895906 · LEWISVILLE, TX 75057 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 03/06/2007
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 03/06/2007 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2020 | 257 | $0.00 |
| 2021 | 2,153 | $0.00 |
| 2022 | 2,503 | $416.56 |
| 2023 | 1,082 | $0.00 |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 5,074 | 341 | $416.56 |
| A4657 | Syringe, with or without needle, each | 462 | 336 | $0.00 |
| 82728 | 58 | 50 | $0.00 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 61 | 37 | $0.00 |
| 83550 | 43 | 38 | $0.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 13 | 12 | $0.00 |
| 83970 | 104 | 101 | $0.00 | |
| 85048 | 62 | 61 | $0.00 | |
| 85041 | 75 | 74 | $0.00 | |
| 83540 | 43 | 38 | $0.00 |